3.4.21.22: coagulation factor IXa
This is an abbreviated version!
For detailed information about coagulation factor IXa, go to the full flat file.
Word Map on EC 3.4.21.22
-
3.4.21.22
-
hemophilia
-
bleeding
-
clot
-
prothrombin
-
thrombin
-
thromboplastin
-
anticoagulant
-
platelet
-
thrombosis
-
antithrombin
-
viiia
-
x-linked
-
heparin
-
adeno-associated
-
fibrinogen
-
plasma-derived
-
willebrand
-
prophylaxis
-
k-dependent
-
infusions
-
prophylactic
-
hemostatic
-
zymogen
-
procoagulant
-
haemostasis
-
fixa
-
thrombogenicity
-
gamma-carboxyglutamic
-
one-stage
-
coagulopathy
-
thromboembolic
-
anti-factor
-
amidolytic
-
on-demand
-
high-purity
-
fibrinopeptide
-
d-dimer
-
thrombin-antithrombin
-
exosite
-
arthropathy
-
prekallikrein
-
cryoprecipitate
-
medicine
-
gamma-carboxylation
-
rfviia
-
bethesda
-
alloantibodies
-
prothrombinase
-
thrombin-activated
-
diathesis
-
novoseven
- 3.4.21.22
- hemophilia
- bleeding
- clot
- prothrombin
- thrombin
- thromboplastin
-
anticoagulant
- platelet
- thrombosis
- antithrombin
- viiia
-
x-linked
- heparin
-
adeno-associated
- fibrinogen
-
plasma-derived
- willebrand
-
prophylaxis
-
k-dependent
-
infusions
-
prophylactic
-
hemostatic
- zymogen
-
procoagulant
-
haemostasis
- fixa
-
thrombogenicity
-
gamma-carboxyglutamic
-
one-stage
- coagulopathy
-
thromboembolic
-
anti-factor
-
amidolytic
-
on-demand
-
high-purity
-
fibrinopeptide
-
d-dimer
-
thrombin-antithrombin
-
exosite
- arthropathy
- prekallikrein
-
cryoprecipitate
- medicine
-
gamma-carboxylation
- rfviia
-
bethesda
-
alloantibodies
- prothrombinase
-
thrombin-activated
- diathesis
- novoseven
Reaction
Selective cleavage of Arg-/-Ile bond in factor X to form factor Xa =
Synonyms
activated Christmas factor, activated coagulation factor IX, activated factor IX, activated FIX, blood coagulation factor IXa, Christmas factor, circulating factor IXa, coagulation factor IX, coagulation factor IXa, factor IX, factor IXa, factor IXaAL, factor IXaalpha, factor IXabeta, factor IXabeta', factor IXaCH, factor IXalphabeta, factor IXaN, factor XIa, FIX, FIXa, FIXC, Gla-domainless factor IXabeta', human coagulation factor IXa, intrinsic Xase, More
ECTree
Advanced search results
Turnover Number
Turnover Number on EC 3.4.21.22 - coagulation factor IXa
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
2.01
methoxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
5.67
methylsulfonyl-D-cyclohexylglycyl-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
6.11
methylsulfonyl-D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide
-
rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol
additional information
2-[5-Amino-2-(4-fluoro-phenyl)-6-oxo-6H-pyrimidin-1-yl]-N-(1-benzyl-2-oxo-2-thiazol-2-yl-ethyl)-acetamide
0.005
mutant enzyme FIXagamma225P
0.058
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of 200 mM Na+
0.63
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of 200 mM Na+
0.78
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of Ca2+ and 185 mM Na+
0.89
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
mutant enzyme FIXagamma225P, in presence of 200 mM Ca2+
3.15
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of 200 mM Ca2+
3.38
4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide
wild type enzyme FIXa, in presence of Ca2+ and 185 mM Na+
18.5
-
pH 7.5, 22°C, in presence of 5 mM Ca2+
18.5
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
pH 7.5, 37°C, recombinant wild-type enzyme, in absence of NaCl
19
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M LiCl
20.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M NaCl
20.2
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
pH 7.5, 37°C, recombinant wild-type enzyme, in presence of 0.2 M NaCl
21.3
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M ChCl
21.9
CH3SO2-D-Leu-Gly-Arg-4-nitroanilide
-
pH 7.5, 22°C, in presence of 5 mM Ca2+ and 0.2 M RbCl
0.00011
-
mutant Y94F/K98T/Y177F, FX activation in presence of FVIIIa
-
0.0002
Factor X
-
mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in presence of FVIIIa
-
0.00023
Factor X
-
25°C, pH 7.4, in the presence of GIGAVLKVLTTGLPALISSWIKRKRQQ
-
0.00088
Factor X
-
mutant Y94F/K98T/Y177F/I213V/E219, FX activation in presence of FVIIIa
-
0.00096
Factor X
-
mutant enzyme E410H, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.00096
Factor X
-
mutant enzyme E410N, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.001
Factor X
-
mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in absence of FVIIIa
-
0.00105
Factor X
-
mutant enzyme E410A, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.0012
Factor X
-
mutant enzyme E410L, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.00127
Factor X
-
wild type enzyme, in the absence of factor VIIIa, at pH 7.4 and 37°C
-
0.00157
Factor X
-
wild type enzyme, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.0022
Factor X
-
mutant Y94F/K98T/Y177F/I213V/E219, FX activation in absence of FVIIIa
-
0.00248
Factor X
-
mutant enzyme E410N, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.00361
Factor X
-
mutant enzyme E410L, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.00397
Factor X
-
mutant enzyme E410H, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.00399
Factor X
-
mutant enzyme E410A, in the presence of factor VIIIa, at pH 7.4 and 37°C
-
0.048
Factor X
-
in the presence of emicizumab, pH and temperature not specified in the publication
-
0.38
Factor X
-
25°C, pH 7.4, in the presence of phospholipid vesicle containing 79% phosphatidylcholine, 1% phosphatidylserine and 20% phosphatidylethanolamine
-
1
Factor X
-
FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22°C, pH not specified in the publication
-
1.9
Factor X
-
pH 7.4, 22°C, recombinant mutant R165A the intrinsic tenase complex, in absence of ethylene glycol
-
2.1
Factor X
-
in the presence of factor VIIIa, pH and temperature not specified in the publication
-
2.9
Factor X
mutant enzyme rFIXa104A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
2.9
Factor X
mutant enzyme rFIXa94A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
3.2
Factor X
-
chimera enzyme FIXaN, in the presence of SFLLRN-activated platelets
-
3.3
Factor X
-
chimera enzyme FIX7EGF2, in the presence of SFLLRN-activated platelets
-
3.3
Factor X
mutant enzyme rFIXa107A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
3.4
Factor X
plasma-derived FIXa, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
3.5
Factor X
-
wild type enzyme, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22°C, pH not specified in the publication
-
3.8
Factor X
-
chimera enzyme FIX7omegaloop, in the presence of SFLLRN-activated platelets
-
3.8
Factor X
mutant enzyme rFIXa105A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
4.1
Factor X
mutant enzyme rFIXa90A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
5.08
Factor X
-
pH 7.4, 22°C, recombinant mutant N178A the intrinsic tenase complex, in absence of ethylene glycol
-
5.2
Factor X
mutant enzyme rFIXa91A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
5.2
Factor X
-
pH 7.4, 22°C, recombinant mutant K126A the intrinsic tenase complex, in absence of ethylene glycol
-
5.47
Factor X
-
pH 7.4, 22°C, recombinant mutant K132A the intrinsic tenase complex, in absence of ethylene glycol
-
5.51
Factor X
-
pH 7.4, 22°C, recombinant wild-type enzyme the intrinsic tenase complex, in absence of ethylene glycol
-
5.6
Factor X
-
pH 7.4, 22°C, recombinant mutant N129A the intrinsic tenase complex, in absence of ethylene glycol
-
16.6
Factor X
mutant enzyme rFIXa89A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 °C
-
600
Factor X
-
pH 7.4, 22°C, recombinant mutant N178A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1000
Factor X
-
pH 7.4, 22°C, recombinant mutant R165A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1340
Factor X
-
pH 7.4, 22°C, recombinant wild-type enzyme and mutant N129A, each in the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1780
Factor X
-
pH 7.4, 22°C, recombinant mutant K132A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
1999
Factor X
-
pH 7.4, 22°C, recombinant mutant K126A the intrinsic tenase complex, in presence of 30% ethylene glycol
-
17.5
-
FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22°C
21.4
L-Leu-Gly-L-Arg-4-nitroanilide
-
wild type enzyme, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22°C
additional information
2-[5-Amino-2-(4-fluoro-phenyl)-6-oxo-6H-pyrimidin-1-yl]-N-(1-benzyl-2-oxo-2-thiazol-2-yl-ethyl)-acetamide
-
the catalytic efficiency kcat/Km, of phospholipid vesicles containing 20 or 35% phosphatidylethanolamine and no phosphatidylserine is 5.5fold higher than that of vesicles containing 1% phosphatidylserine and no phosphatidylethanolamine
additional information
additional information
-
the catalytic efficiency kcat/Km, of phospholipid vesicles containing 20 or 35% phosphatidylethanolamine and no phosphatidylserine is 5.5fold higher than that of vesicles containing 1% phosphatidylserine and no phosphatidylethanolamine
-